ClinicalTrials.gg
CompletedNCT01227577MACS1428Updated Feb 8, 2016Results posted

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

A Phase 4 interventional study of Nilotinib in Chronic Myelogenous Leukemia in Chronic Phase, sponsored by Novartis Pharmaceuticals. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
20th of 66
128 · median 55
Started
2010
with 2 others
Phase 4
12 of 66
1 open now
Registered
23rd of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 20th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 4, and was the 23rd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

"This is a single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP). The study is designed to evaluate early and deep molecular responses up to 4 years on nilotinib treatment. The primary end point is Rate of confirmed CMR in newly diagnosed Philadelphia chromosome positive CML-CP patients."

03

Conditions studied

  • Chronic Myelogenous Leukemia in Chronic Phase

Keywords

  • CML
  • Chronic Myelogenous Leukemia
  • Leukemia
  • CML-CP
  • Nilotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with Ph+ CML-CP within 3 months of diagnosis. Male or female patients' ≥ 18 years of age. Patients must have adequate end organ function.

Exclusion criteria

Exclusion Criteria:

Previously documented T315I mutation. Other CML treatment is an exclusion criteria with the following exception: While awaiting study start, patients may be treated with anagrelide (no treatment duration limit), hydroxyurea (no treatment duration limit), and/or up to a 14 day supply of a tyrosine kinase inhibitor (TKI) approved by the FDA for frontline treatment. Patients taking a TKI prior to study entry must have at least a one day washout from their last dose of medication and have recovered from any side effects of such therapy.

Impaired cardiac function as defined by the protocol. Patients with to receiving nilotinib, including concomitant medications.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.

    Drug: Nilotinib

Interventions

  • Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Confirmed Complete Molecular Response (CMR)

    CMR was defined as at least 4.5 log reduction of breakpoint cluster region gene/Abelson proto-oncogene (Bcr-Abl) transcipts from the standardized baseline on the international scale (equivalent to Bcr-Abl \<=0.0032% IS) with a minimum of 25,614 ABL control copies. CMR was to be confirmed by a second polymerase chain reaction (PCR) sample drawn 3 months later where the results should be less than or equal to 0.0032% with a minimum of 25,614 Abelson proto-oncogene (ABL) control copies.

    Time frame: 4 years

Secondary outcomes

  1. Number of Participants With Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR)

    CCyR was defined as 0% Philadelphia chromosome-positive (Ph+) metaphases in the bone marrow. MMR was defined as a 3 log reduction of Bcr-Abl transcripts from the standardized baseline on the international scale (equivalent to Bcr-Abl ≤ 0.1% IS). Bcr-Abl transcripts assessed by peripheral blood quatitative real time polymerase chain reaction (RQ-PCR) were used for the determination of all molecular responses.

    Time frame: 4 years

  2. Time to CMR, CCyR and MMR

    Time to CMR, CCyR, and MMR was defined as the time from the date of enrollment to the date of first documented CMR, CCyR and MMR, respectively.

    Time frame: 4 years

  3. Duration of CMR, CCyR and MMR

    Duration of CMR, CCyR and MMR were defined as the time from the first date of achievement of the response to the date of first documented loss of the response.

    Time frame: 4 years

  4. Number of Participants With Progression to Accelerated Phase/Blastic Crisis (AP/BC)

    Progression to AP/BC is defined as loss of CCyR, MMR, and CMR and was summarized by frequencies and percentages.

    Time frame: 4 years

  5. Time to Progression of AP/BC

    Time to progression of AP/BC was defined as the time from the date of the first dose of study drug to the date of first documented progression of AP/BC.

    Time frame: 4 years

  6. Number of Participants With Loss of CCyR, MMR and CMR

    Rate of loss of CMR was defined as an increase in the Bcr-Abl transcripts to greater than 0.0032% IS. Rate of loss of CCyR was defined as an increase in the Ph+ bone marrow cells to greater than 0%. Rate of loss of MMR was defined as an increase in the Bcr-Abl transcripts to greater than 0.1% IS.

    Time frame: 4 years

  7. Number of Participants With CMR Who Were Dosed to 400 mg b.i.d.

    CMR was defined as at least 4.5 log reduction of breakpoint cluster region gene/Abelson proto-oncogene (Bcr-Abl) transcipts from the standardized baseline on the international scale (equivalent to Bcr-Abl \<=0.0032% IS) with a minimum of 25,614 ABL control copies. CMR was to be confirmed by a second polymerase chain reaction (PCR) sample drawn 3 months later where the results should be less than or equal to 0.0032% with a minimum of 25,614 Abelson proto-oncogene (ABL) control copies.

    Time frame: 4 years

  8. Event-free Survival, Progression-free Survival and Overall Survival

    Event-free survival was defined as the time from the date of enrollment to the date of first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of CCyR, loss of Partial Cytogenetic Response (PCyR), progression to the accelerated phase or blast crisis, and death from any cause. Progression-free survival was defined as the time from the date of enrollment to the date of first occurrence of any of the following: progression to the accelerated phase or blast crisis, death, and loss of CMR. Overall survival was defined as the time from the date of enrollment until death due to any cause.

    Time frame: 4 years

07

Results

Posted Feb 8, 2016

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started128
Completed93
Not completed35
Withdrew: Protocol deviation3
Withdrew: Death3
Withdrew: Administrative problems2
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject4
Withdrew: Lack of efficacy5
Withdrew: Adverse event17

Outcome measures

PrimaryNumber of Participants With Confirmed Complete Molecular Response (CMR)

CMR was defined as at least 4.5 log reduction of breakpoint cluster region gene/Abelson proto-oncogene (Bcr-Abl) transcipts from the standardized baseline on the international scale (equivalent to Bcr-Abl \<=0.0032% IS) with a minimum of 25,614 ABL control copies. CMR was to be confirmed by a second polymerase chain reaction (PCR) sample drawn 3 months later where the results should be less than or equal to 0.0032% with a minimum of 25,614 Abelson proto-oncogene (ABL) control copies.

Time frame:
4 years
Reported as:
Number · Participants
Number of Participants With Confirmed Complete Molecular Response (CMR)
ParticipantsNilotinib
Number of Participants With Confirmed Complete Molecular Response (CMR)34
SecondaryNumber of Participants With Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR)

CCyR was defined as 0% Philadelphia chromosome-positive (Ph+) metaphases in the bone marrow. MMR was defined as a 3 log reduction of Bcr-Abl transcripts from the standardized baseline on the international scale (equivalent to Bcr-Abl ≤ 0.1% IS). Bcr-Abl transcripts assessed by peripheral blood quatitative real time polymerase chain reaction (RQ-PCR) were used for the determination of all molecular responses.

Time frame:
4 years
Reported as:
Number · Participants
Number of Participants With Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR)
ParticipantsNilotinib
CCyR93
MMR94
SecondaryTime to CMR, CCyR and MMR

Time to CMR, CCyR, and MMR was defined as the time from the date of enrollment to the date of first documented CMR, CCyR and MMR, respectively.

Time frame:
4 years
Reported as:
Median · Months
Time to CMR, CCyR and MMR
MonthsNilotinib
CMR (n=34)NA (NA to NA)
CCyR (n=93)5.5 (4.07 to 5.55)
MMR (n=94)5.7 (5.55 to 7.66)
SecondaryDuration of CMR, CCyR and MMR

Duration of CMR, CCyR and MMR were defined as the time from the first date of achievement of the response to the date of first documented loss of the response.

Time frame:
4 years
Reported as:
Mean · Months
Duration of CMR, CCyR and MMR
MonthsNilotinib
CMR (n=34)7.97 ± 3.705
CCyR (n=93)NA ± NA
MMR (n=94)4.86 ± 5.003
SecondaryNumber of Participants With Progression to Accelerated Phase/Blastic Crisis (AP/BC)

Progression to AP/BC is defined as loss of CCyR, MMR, and CMR and was summarized by frequencies and percentages.

Time frame:
4 years
Reported as:
Number · Participants
Number of Participants With Progression to Accelerated Phase/Blastic Crisis (AP/BC)
ParticipantsNilotinib
Number of Participants With Progression to Accelerated Phase/Blastic Crisis (AP/BC)1
SecondaryTime to Progression of AP/BC

Time to progression of AP/BC was defined as the time from the date of the first dose of study drug to the date of first documented progression of AP/BC.

Time frame:
4 years
Reported as:
Median · Months
Time to Progression of AP/BC
MonthsNilotinib
Time to Progression of AP/BCNA (NA to NA)
SecondaryNumber of Participants With Loss of CCyR, MMR and CMR

Rate of loss of CMR was defined as an increase in the Bcr-Abl transcripts to greater than 0.0032% IS. Rate of loss of CCyR was defined as an increase in the Ph+ bone marrow cells to greater than 0%. Rate of loss of MMR was defined as an increase in the Bcr-Abl transcripts to greater than 0.1% IS.

Time frame:
4 years
Reported as:
Number · Participants
Number of Participants With Loss of CCyR, MMR and CMR
ParticipantsNilotinib
CMR (n=34)6
CCyR (n=93)0
MMR (n=94)13
SecondaryNumber of Participants With CMR Who Were Dosed to 400 mg b.i.d.

CMR was defined as at least 4.5 log reduction of breakpoint cluster region gene/Abelson proto-oncogene (Bcr-Abl) transcipts from the standardized baseline on the international scale (equivalent to Bcr-Abl \<=0.0032% IS) with a minimum of 25,614 ABL control copies. CMR was to be confirmed by a second polymerase chain reaction (PCR) sample drawn 3 months later where the results should be less than or equal to 0.0032% with a minimum of 25,614 Abelson proto-oncogene (ABL) control copies.

Time frame:
4 years
Reported as:
Number · Participants
Number of Participants With CMR Who Were Dosed to 400 mg b.i.d.
ParticipantsNilotinib
Number of Participants With CMR Who Were Dosed to 400 mg b.i.d.0
SecondaryEvent-free Survival, Progression-free Survival and Overall Survival

Event-free survival was defined as the time from the date of enrollment to the date of first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of CCyR, loss of Partial Cytogenetic Response (PCyR), progression to the accelerated phase or blast crisis, and death from any cause. Progression-free survival was defined as the time from the date of enrollment to the date of first occurrence of any of the following: progression to the accelerated phase or blast crisis, death, and loss of CMR. Overall survival was defined as the time from the date of enrollment until death due to any cause.

Time frame:
4 years
Reported as:
Median · Months
Event-free Survival, Progression-free Survival and Overall Survival
MonthsNilotinib
Event-freeNA (NA to NA)
Progression-freeNA (NA to NA)
OverallNA (NA to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—27/128 (21.1%)122/128 (95.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventNilotinib
Abdominal painGastrointestinal disorders4/128
Myocardial infarctionCardiac disorders3/128
PancreatitisGastrointestinal disorders3/128
PneumoniaInfections and infestations3/128
NeutropeniaBlood and lymphatic system disorders2/128
ThrombocytopeniaBlood and lymphatic system disorders2/128
Chest painGeneral disorders2/128
Atrial fibrillationCardiac disorders1/128
PalpitationsCardiac disorders1/128
HyperthyroidismEndocrine disorders1/128
Most frequent other events
Showing 10 of 58
Most frequent other events
EventNilotinib
FatigueGeneral disorders58/128
RashSkin and subcutaneous tissue disorders48/128
NauseaGastrointestinal disorders45/128
Lipase increasedInvestigations31/128
HeadacheNervous system disorders31/128
ConstipationGastrointestinal disorders30/128
DiarrhoeaGastrointestinal disorders29/128
DyspnoeaRespiratory, thoracic and mediastinal disorders26/128
ArthralgiaMusculoskeletal and connective tissue disorders25/128
Abdominal painGastrointestinal disorders24/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nilotinib
Mean55.6 ± 14.99
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female64
Male64
08

Study locations

32 sites
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
    Burbank, California 91505-6866, United States
  • Bay Area Cancer Research Dept.ofBayAreaCancerResearch
    Concord, California 94520, United States
  • St. Jude Heritage Medical Group Virginia Crosson Cancer Center
    Yorba Linda, California 92886, United States
  • Sarah Cannon Research Institute SCRI
    Jacksonville, Florida 32256, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Pasco Hernando Oncology
    New Port Richey, Florida 34652, United States
  • Georgia Regents University MedCollege of GA Cancer Ctr 2
    Augusta, Georgia 30912, United States
  • Stroger Cook County Hospital Division of Hematology & Onc
    Chicago, Illinois 60612, United States
  • Louis A. Weiss Memorial Hospital
    Chicago, Illinois 60640, United States
  • Indiana Blood and Marrow Institute
    Beach Grove, Indiana 46107, United States
  • Cancer Center of Kansas
    Witchita, Kansas 67214-3728, United States
  • LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3)
    New Orleans, Louisiana 70115, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • St. Louis University Cancer Center
    St. Louis, Missouri 63110, United States
  • University of Nebraska Medical Center University of Nebraska Med Ctr
    Omaha, Nebraska 68198, United States
  • Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • University of Rochester Medical Ct James P Wilmot Cancer Ctr
    Rochester, New York 14642, United States
  • Duke University Medical Center Duke University Med Ctr
    Durham, North Carolina 27710, United States
  • Oregon Health & Science University
    Portland, Oregon 97201, United States
  • Cancer Centers of the Carolinas Cancer Center
    Greenville, South Carolina 29605, United States
  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
    Chattanooga, Tennessee 37404, United States
  • The Jones Clinic
    Germantown, Tennessee 38138, United States
  • Tennessee Oncology Sarah Cannon Research Inst.
    Nashville, Tennessee 37203, United States
  • Baylor Research Institute Baylor Research Institute (17)
    Dallas, Texas 75204, United States
  • Oncology Consultants Oncology Consultants, P.A.
    Houston, Texas 77024, United States
  • Millennium Oncology
    Houston, Texas 77090, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
09

References and documents

Publications

  • Berdeja JG, Heinrich MC, Dakhil SR, Goldberg SL, Wadleigh M, Kuriakose P, Cortes J, Radich J, Helton B, Rizzieri D, Paley C, Dautaj I, Mauro MJ. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. Leuk Lymphoma. 2019 Oct;60(10):2384-2393. doi: 10.1080/10428194.2019.1590569. Epub 2019 Mar 26. PubMed 30912699 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2010
First posted
Oct 25, 2010
Start
Nov 2010
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Feb 8, 2016
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01227577
Responsible party
Sponsor
First posted
Oct 25, 2010
Start date
Nov 2010
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Feb 8, 2016
Last update
Feb 8, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion